JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Butelman, E. R.
Right arrow Articles by Kreek, M.-J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Butelman, E. R.
Right arrow Articles by Kreek, M.-J.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 290, Issue 2, 678-686, August 1999

Effects of Systemically Administered Dynorphin A(1-17) in Rhesus Monkeys1

Eduardo R. Butelman, Todd J. Harris, Amarilis Perez and Mary-Jeanne Kreek

Laboratory on the Biology of Addictive Diseases, Rockefeller University, New York, New York

The effects of i.v. dynorphin A(1-17) and its main nonopioid biotransformation fragment, dynorphin A(2-17), were compared in rhesus monkeys with those of the selective kappa -opioid agonist, U69,593, in assays of operant behavior, thermal antinociception, and neuroendocrine function (prolactin release). Dynorphin A(1-17) (0.1-3.2 mg/kg i.v.) and U69,593 (0.001-0.032 mg/kg s.c.) decreased rates of schedule-controlled (fixed ratio 20) food-reinforced responding, whereas dynorphin A(2-17) (1-3.2 mg/kg i.v.) was ineffective. Pretreatment studies with the opioid antagonist quadazocine (0.32 mg/kg s.c.) revealed that the operant effects of dynorphin A(1-17) were not mediated by kappa - or µ-opioid receptors. A different profile was observed in the warm water tail withdrawal assay of thermal antinociception, where both dynorphin A(1-17) and A(2-17) (0.032-3.2 mg/kg i.v., n = 4) were modestly effective in 50°C water, and both were ineffective in 55°C water. By comparison, U69,593 (0.032-0.18 mg/kg s.c.) was maximally effective in 50°C water and partially effective in 55°C. kappa -opioid agonists increase serum levels of prolactin in animals and humans. Dynorphin A(1-17) (ED50 = 0.0011 mg/kg i.v.), similar to U69,593 (ED50 = 0.0030 mg/kg i.v.), was very potent in increasing serum prolactin levels in follicular phase female rhesus monkeys, whereas dynorphin A(2-17) (0.32 mg/kg i.v.) was ineffective. The effects of dynorphin A(1-17) and U69,593 on serum prolactin were both antagonized by quadazocine (0.32 mg/kg s.c.) in a surmountable manner, consistent with opioid receptor mediation. The present studies show that serum prolactin levels are a sensitive quantitative endpoint to study the systemic effects of the endogenous opioid peptide, dynorphin A(1-17), in primates.


0022-3565/99/2902-0678$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, J. W. Ball, T. J. Harris, and M. J. Kreek
Topical Capsaicin-Induced Allodynia in Unanesthetized Primates: Pharmacological Modulation
J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1106 - 1114.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
G. Bart, L. Borg, J. H. Schluger, M. Green, A. Ho, and M. J. Kreek
Suppressed Prolactin Response to Dynorphin A1-13 in Methadone-Maintained Versus Control Subjects
J. Pharmacol. Exp. Ther., August 1, 2003; 306(2): 581 - 587.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
E. R. Butelman, M. C. H. Ko, J. R. Traynor, J. A. Vivian, M.-J. Kreek, and J. H. Woods
GR89,696: A Potent kappa -Opioid Agonist with Subtype Selectivity in Rhesus Monkeys
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1049 - 1059.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
M. C. H. Ko, M. D. Johnson, E. R. Butelman, K. J. Willmont, H. I. Mosberg, and J. H. Woods
Intracisternal Nor-Binaltorphimine Distinguishes Central and Peripheral kappa -Opioid Antinociception in Rhesus Monkeys
J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1113 - 1120.
[Abstract] [Full Text]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.